All posts by student

Ferring Announces New Analysis of Rekovelle Data Relating to … – Business Wire (press release)

SAINT-PREX, Switzerland--(BUSINESS WIRE)--Ferring Pharmaceuticals announced today a new analysis of Rekovelle (follitropin delta) data that showed cumulative live birth rates were similar between women receiving Rekovelle and conventional follitropin alfa treatment.1 In addition, Rekovelle data from a separate new analysis showed a favourable safety profile in women with high anti-Mllerian hormone (AMH) levels.2 These analyses of the ESTHER-1 and ESTHER-2 Phase III clinical trials3,4 were presented today at the 33rd Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE) in Geneva, Switzerland.

Rekovelles individualised dosing regimen, based on a patients AMH level and body weight, provides clinicians with a consistent, evidence-based approach to personalising treatment for their patients, said Per Falk, Executive Vice President and Chief Scientific Officer, Ferring Pharmaceuticals. These new Rekovelle analyses add further evidence for a personalised approach to fertility treatment for patients.

A new analysis of the ESTHER-1 and ESTHER-2 trials showed that in women undergoing in vitro fertilisation (IVF), the cumulative live birth rate for fresh embryo transfers after three treatment cycles was 43.9% (292/665) with Rekovelle and 44.5% (294/661) with follitropin alfa.1 In addition, ongoing pregnancy rate was 45.1% (300/665) and 45.7% (302/661), respectively.1 The ESTHER trials3,4 were not powered for this analysis, so no confirmatory conclusions can be derived.

A separate new analysis of the ESTHER-1 trial was conducted to evaluate ongoing pregnancy rates, early ovarian hyperstimulation syndrome (OHSS) and preventive interventions for early OHSS in women with different AMH levels.2 For women with high AMH 35 pmol/L (13% of the trial population) the incidence of early OHSS with Rekovelle was lower (4.7%, 4/86) compared with conventional follitropin alfa dosing (11.9%, 10/84). The number of patients requiring preventive interventions for early OHSS was also lower (4.7%, 4/86 and 23.8%, 20/84 respectively). In addition, patients maintained ongoing pregnancy rate.2 The ESTHER trials3,4 were not powered for this analysis, so no confirmatory conclusions can be derived.

- ENDS -

About Rekovelle(follitropin delta) Rekovelle is the first recombinant follicle stimulating hormone (rFSH) derived from a human cell line (PER.C6 cell line).3,5,6,7 It has been developed for individualised dosing based on a patients body weight and serum AMH level, as determined by a companion diagnostic, the Elecsys AMH Plus immunoassay from Roche.3,8,9 Rekovelle is structurally and biochemically distinct from other existing recombinant FSH treatments.3,5,6,7

Rekovelle received Marketing Authorisation from the European Commission (EC) in December 2016.

About the ESTHER trials ESTHER-1 (Evidence-based Stimulation Trial with Human recombinant FSH in Europe and Rest of World) is a Phase 3, randomised, assessor-blind, controlled trial of 1326 patients in 11 countries undergoing their first ART cycle. Patients were randomized 1:1 to receive treatment with individualised Rekovelle, a fixed daily dose based on serum anti-Mllerian hormone (AMH) levels and body weight, or conventional follitropin alfa dosing. The co-primary endpoints of ongoing pregnancy rates and ongoing implantation rates were met and results showed no difference between the two treatment arms. Results of the ESTHER-1 trial were published in the February 2017 issue of Fertility & Sterility.3

ESTHER-2 is a Phase 3, assessor-blind, controlled trial evaluating the immunogenicity of Rekovelle in a subset of ESTHER-1 patients undergoing repeated cycles of controlled ovarian stimulation for ART. Data demonstrated no increased immunogenicity risk with Rekovelle after exposure in repeated cycles.4

About AMH and OHSS AMH is a biomarker used to assess ovarian reserve and can help predict ovarian response.10 Women with high AMH levels are at an increased risk of developing OHSS, a potential complication of IVF treatment.11,12 Symptoms of early OHSS may include abdominal distension or discomfort, nausea and vomiting. In more severe cases OHSS can lead to large amounts of ascites (fluid accumulation in the abdominal cavity), shortness of breath, blood clots, dehydration and potentially, death.11

The prevalence of OHSS in women undergoing IVF varies according to severity, with cases of OHSS experienced by 2033% (mild), 36% (moderate) and 0.12% (severe) of women.13 A recent report suggested that OHSS is an underreported side effect of ovarian stimulation and the real world incidence may be higher.14 In addition to the impact on patients, the treatment of OHSS is associated with significant costs to the healthcare system.15 In the UK for example, the cost of treating moderate and severe cases of OHSS is estimated to be over 7 million every year.15,16

About Ferring Pharmaceuticals Headquartered in Saint-Prex, Switzerland, Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group active in global markets. A leader in reproductive and maternal health, Ferring has been developing treatments for mothers and babies for over 50 years. Today, over one third of the companys research and development investment goes towards finding innovative treatments to help mothers and babies, from conception to birth. The company also identifies, develops and markets innovative products in the areas of urology, gastroenterology, endocrinology and orthopaedics. Ferring has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries. For further information on Ferring or its products, visit http://www.ferring.com.

About the ElecsysAMH Plus immunoassay from Roche The Elecsys AMH Plus immunoassay from Roche has been shown to provide a precise, reliable and robust measurement of AMH levels.8,9,17,18,19,20 This fully automated Elecsys AMH Plus immunoassay, run on the cobase and Elecsys immunoassay analysers, determines AMH levels in 18 minutes, making it appropriate for routine clinical use. The Elecsys AMH Plus immunoassay is intended to be used for assessment of ovarian reserve, prediction of response to COS and establishment of the individual daily dose of Rekovelle in combination with body weight in COS for the development of multiple follicles in women undergoing an assisted reproductive technology programme.8,9,17,18,19,20

References

1 Havelock J, Bosch E, Sanchez F, et al. Cumulative ongoing pregnancy and live birth rates following repeated controlled ovarian stimulation (COS) cycles using individualised follitropin delta dosing compared to conventional follitropin alfa dosing [abstract] In: 33rd Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE); 2017; Geneva, Switzerland. Abstract no. 0-168

2 La Marca A, Nelson S, Gothberg M, et al. The impact of serum anti-Mllerian hormone (AMH) levels on clinical outcome of individualized follitropin delta dosing and conventional follitropin alfa dosing in controlled ovarian stimulation [abstract]. In: 33rd Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE); 2017; Geneva, Switzerland. Abstract no. 0-174

3 Nyboe Andersen A, Nelson SM, Fauser BC, et al. Individualised versus conventional ovarian stimulation for an in vitro fertilization: a multicenter, randomized, controlled assessor-blinded, phase 3 noninferiority trial. Fertil Steril. 2017: 107(2): 387-396

4 Buur Rasmussen A et al. Low immunogenicity potential of follitropin delta, a recombinant FSH preparation produced from a human cell line: Results from phase 3 trials (ESTHER-1 and ESTHER-2). Human Reproduction 2016; 31: 385

5 Rekovelle Summary of Product Characteristics (SmPC) Available at: https://www.medicines.org.uk/emc/medicine/33324 [Last accessed: June 2017]

6 Arce JC, Andersen AN, Fernndez-Snchez M, et al. Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimullerian hormonestratified, doseresponse trial in women undergoing in vitro fertilization/intracytoplasmic sperm injection. Fertil Steril. 2014;102(6):16331640

7 Olsson H, Sandstrm R, Grundemar L. Different pharmacokinetic and pharmacodynamic properties of recombinant follicle-stimulating hormone (rFSH) derived from a human cell line compared with rFSH from a non-human cell line. J Clin Pharmacol. 2014; 54(11):12991307

8 Deeks ED. Elecsys AMH assay: a review in anti-Mllerian hormone quantification and assessment of ovarian reserve. Mol Diagn Ther. 2015; 19: 245-249

9 Roche Diagnostics. Elecsys AMH (anti-Mullerian hormone): Method sheet. 2015. https://pim-eservices.roche.com. [Last accessed June 2017]

10 La Marca A, Sighinolfi G, Radi D, et al. Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update. 2010; 16(2):113-130

11 OHSS Symptoms and Causes. Patient Care and Health Information. Mayo Clinic. http://www.mayoclinic.org/diseases-conditions/ovarian-hyperstimulation-syndrome-ohss/symptoms-causes/dxc-20263586 [Last accessed: June 2017]

12 Salmassi A, Mettler L, et al. Cut-Off Levels of Anti-Mullerian Hormone for the Prediction of Ovarian Response, In Vitro Fertilization Outcome and Ovarian Hyperstimulation Syndrome. Int J Fertil Steril. 2015; 9(2): 157-167

13 Delvigne A, Rozenberg S, et al. Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. Hum Reprod Update. 2002; 8(6): 559-577

14 Thomsen L, Humaidan P, et al. Ovarian hyperstimulation syndrome in the 21st century: the role of gonadotropin-releasing hormone agonist trigger and kisspeptin. Curr Opin Obstet Gynecol. 2015; 27(3): 210-214

15 Yates AP, Rustamov O, Roberts SA, et al. Anti-Mullerian hormone-tailored stimulation protocols improve outcomes whilst reducing adverse effects and costs of IVF. Hum Reprod. 2011; 26(9): 2353-2362

16 Fertility Treatment in 2014 Trends and Figures Report. Human Fertilisation and Embryology Authority. http://www.hfea.gov.uk/docs/HFEA_Fertility_treatment_Trends_and_figures_2014.pdf [Last accessed June 2017]

17 Gassner D, Jung R. First fully automated immunoassay for anti-Mllerian hormone. Clin Chem Lab Med. 2014;52(8):1143-1152

18 Anderson RA, Anckaert E, Bosch E, et al. Prospective study into the value of the automated Elecsys antimllerian hormone assay for the assessment of the ovarian growing follicle pool. Fertil Steril. 2015;103(4):107480.e4

19 Nelson SM, Pastuszek E, Kloss G, et al. Two new automated, compared with two enzyme-linked immunosorbent antimllerian hormone assays. Fertil Steril. 2015;104(4):1016-1021.e6

20 Hyldgaard J, Bor P, Ingerslev HJ, et al. Comparison of two different methods for measuring anti-mullerian hormone in a clinical series. Reprod Biol Endocrinol. 2015;13(1):107

See more here:
Ferring Announces New Analysis of Rekovelle Data Relating to ... - Business Wire (press release)

Male partner’s age can affect IVF delivery success: Study – Independent Online

The study of almost 19 000 IFV treatment cycles showed a decline in the success rate with increasing male partner age.

"Our study found an independent effect of male age on the cumulative incidence of live birth," said investigator Laura Dodge from Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, US.

The study, scheduled to be presented at the European Society of Human Reproduction and Embryology meeting in Geneva on Tuesday, was an analysis of all IVF cycles performed at a large IVF centre in the Boston region between 2000 and 2014, a total of almost 19 000 cycles performed in 7753 couples.

The female partners in these cycles were stratified according to four age bands - under 30, 30-35 years, 35-40 years and 40-42.

Men were stratified into these same four age bands, with an additional band of 42 and over.

As expected, the cumulative live birth rate (measured from up to six cycles of treatment) was lowest in those couples where the female partner was in the 40-42 age band, and in this group the age of the male partner had no impact, demonstrating the dominant detrimental effect of female age.

However, within the other bands of female age, the cumulative incidence of live birth was significantly affected by male partner age and was found to decline as the man grew older.

For example, in couples with a female partner aged under 30, a male partner aged 40-42 was associated with a significantly lower cumulative birth rate (46 percent) than a male partner aged 30-35 (73 percent).

Similarly, in couples with a female partner aged 35-40 years live birth rates were higher with a younger than with an older male partner.

"Women aged 35-40 did significantly benefit from having a male partner who is under age 30, in that they see a nearly 30% relative improvement in cumulative incidence of live birth when compared to women whose partner is 30-35 - from 54 percent to 70 percent," Dodge said.

For women between ages 30 and 35, having a partner who is older than they are is associated with approximately 11 percent relative decreases in cumulative incidence of live birth when compared with having a male partner within their same age band, Dodge said.

In natural conceptions increasing male age is associated with a decreased incidence of pregnancy, increased time to pregnancy, and increased risk of miscarriage, Dodge noted.

The mechanisms, she added, are unclear but may include impaired semen parameters, increased DNA damage in sperm, and epigenetic alterations in sperm that affect fertilisation, implantation, or embryo development.

-IANS

See the original post:
Male partner's age can affect IVF delivery success: Study - Independent Online

Genetics of Earlobes – News-Medical.net

Similar to the human eyes, nose, and lips, the earlobes also have special features. Although the human ears look similar, there are minor structural differences that make each ear different from the other.

The major form of the gene that determines the shape of the earlobe is known as an allele. An allele is a gene which is found at a specific position on a chromosome. It has been established that all genes in our body have two copies; one from each parent.

Image Credit: Thiti Sukapan / Shutterstock

An earlobe is made up of connective tissues combined with a mixture of areola tissues and fat cells. Earlobes have a good blood supply which help in keeping them warm and maintaining balance. Majorly, there are two types of earlobes found in humans - free earlobes and attached earlobes.

Free Earlobes: Free earlobes are the most common form of lobes found. This type of earlobe is often large and hangs below the point of attachment to the head. This happens due to the influence of a dominant allele. If the genes from the parents get expressed by the dominant allele, then the child will be born with free earlobes.

In most cases, the allele is regnant to the free lobes compared to attached lobes. The free earlobe parents can also give birth to an attached earlobe child, depending on the reaction of the allele gene. If parents with free earlobes give birth to a baby with attached earlobes, it is certain that both of them had both a copy of the dominant and recessive allele.

Attached Earlobes: These types of earlobes are not rare, but are also not commonly found. Earlobes of such type are small in size and do not have hangs. They are attached directly to the side of the head. The structural formation of this kind of lobe is due to the absence of the dominant allele in the chromosomes. The recessive allele is expressed instead in the chromosomes to form an attached earlobe. It is not necessary that parents with attached earlobes should give birth only to the attached earlobe child.

Traits are the major factors that result from chromosome pairs and which, in turn, determine ones overall physical appearance. When alleles combine, some exert stronger influence down sythan the others. The stronger allele is responsible for the dominant traits. Dominant alleles are said to be found throughout an organism. If the dominant allele fails to show its presence, the recessive allele will be expressed. These are known as recessive traits. Although the traits vary, the size of the earlobes for both the traits remain the same. An average mans ear measures 6cm, while for a woman it is about 5cm, in which the earlobe size measures about 2cm.

Genetic conditions play an important role in the birth of a human being. People born with abnormal growth of organs are considered to be affected by the traits before their birth. The major conditions that cause irregular or abnormal growth include:

Birth disorders may be minor or severe and may occur at any stage during pregnancy. Most disorders affect the baby while in the womb, before the formation of the organs; however, not all genetic defects are caused by the transfer of gene from the parents. In many cases, the baby may be born with genetic disorders that the parents gene does not contain. Some defects are considered to be harmless, while some may require prolonged medical treatment.

Read the original:
Genetics of Earlobes - News-Medical.net

NHS to offer personal cancer care based on patients’ genetics – iNews

A new era of genome-based personalised medicine for cancer could be in place within five years under plans unveiled by the Chief Medical Officer.

The genomics dream outlined by Professor Dame Sally Davies would see millions of patients having all their DNA tested as genome sequencing becomes as routine as MRI or CT scans.

Ultimately, the future goal is for every cancer patient to have his or her whole genome sequenced, making the procedure as standard as blood tests and biopsies. People with rare diseases are also expected to benefit from having greater access to the technology, ending the years-long diagnostic odyssey of multiple tests and visits to different specialists.Whole genome sequencing involves unscrambling the entire book of genetic instructions that make us what we are, encompassing 3.2 billion letters of code.

Research suggests that in 60 per cent of cases, the genomes of cancer patients reveal actionable data personal mutations that can shape future treatment.

Tens of thousands of NHS patients have already had their DNA mapped, but the recommendations set out in Dame Sallys Generation Genome report aim to multiply the numbers many times over.

Dame Sally said: The age of precision medicine is now and the NHS must act fast to keep its place at the forefront of global science .

This technology has the potential to change medicine forever but we need all NHS staff, patients and the public to recognise and embrace its huge potential.

Genomic medicine has huge implications for the understanding and treatment of rare diseases, cancer and infections.

Currently, genetic testing of NHS patients in England is conducted via 25 regional laboratories and a plethora of smaller units operating along the lines of a cottage industry, Dame Sally said.

Her chief recommendation is to centralise all the labs and establish a national network providing equal access to the tests across the country.

Within government, a new National Genomics Board would be set up, chaired by a minister, to oversee the expansion and development of genomic services, taking into account new advances within the rapidly evolvingtechnology.

The Health Secretary, Jeremy Hunt, said he welcomed the report, pointing out that the UK had established itself as a world leader in genomics medicine. He added: Tens of thousands of patients across the country have already benefited from quicker diagnosis, precise treatment and care, and we will support the NHS to continue its relentless drive to push the boundaries of modern science.

Part of what made greater access to whole genome sequencing feasible was the rapidly falling cost of the tests, which has dropped from several thousand pounds to 680.

Reporting by John von Radowitz, Press Association

Achieving the genomics dream could make a huge difference to the 3.5 million adults and children with one of the 7,000 recognised rare diseases that could be treated far more quickly and more effective with genome testing.

Every persons genome contains 3.2 billion letters of genetic code, amounting to two terabytes of data. If it was printed your genome would fill a stack of books 61 metres high. Although officials now talk about personalised medicine, what they are trying to deliver is diagnosis and treatment related to the genomic signature of a particular patient.

This means giving the most effective drugs against cancer, using drugs which will cause fewer side effects, seeking new drugs and treatments and moving to personalised prevention. There will also be other applications, many of which we are not yet aware of, the report says.

In the case of cancer, tumour cells develop a different genome to normal cells. Comparing a patients normal and cancerous DNA can provide valuable clues about the best form of treatment, although this information is not set in stone. Cancers evolve rapidly and alter their DNA, which can make them resistant to treatments.

This is still much more to learn about genomes and their relation with treatment response, but once that knowledge base expands there should be much faster diagnosis of rare diseases which currently take on average four years to diagnose.

Paul Gallagher

Originally posted here:
NHS to offer personal cancer care based on patients' genetics - iNews

Jared Wareham; The Genetic Paradox – CattleNetwork.com

Throughout human existence it has been our nature to push the envelope. More speed. More power. More performance. Ingenuity combined with trial and error spawn new peaks in technology.

As we strive to stay ahead of the technological advancement curve, we sometimes forget about the interconnected systems that might need time and adjustment to catch up. Too much torque and the transmissions or drivelines wear out easily. Increases in output translate into greater input requirements and higher priced fuels. At some point, the law of diminishing returns kicks in, making that next increase to performance or production too costly and economically inefficient. Much of the same can be said of beef genetics.

It is amazing how much progress our industry has made in genomics in such little time. Genetic improvement is absolutely vital for every segment of our industry because it helps promote multiple elements linked to sustainability. However, producers need to be mindful of the inevitable trade-off that comes with a rapidly accelerated discovery curve.

Decades ago, the push for performance was inadvertently tied to frame. Mature size and calving difficulties almost singlehandedly devastated the marketability of many breeds. Though unintended, the consequences were still significant. It is no different than the push for muscle cars with powerful stances and large throaty motors that also guzzled fuel by the gallon.

Oddly enough, we have corrected cow size, yet cow maintenance or input cost remains a common issue. If you install a high performance racing engine in a car, it will require a grade of fuel of equal magnitude to perform up to its potential. Cheap, poor quality fuels simply wont do. The same is true for your cowherd. If you continue to select for growth and milk genetics, be prepared to adjust the feed input requirements that will follow. Our push to discover that next elite genetic package is changing the beef herd from independent foragers to concentrate dependents.

There are other phenotypic systems that desperately need to catch up with a hastily advancing genotype population. Evidence of this can be seen in the national beef herd by simply looking at their feet. The push to discover cattle that can be marketed as the next top genetic package for extreme calving ease, growth and marbling, is creating a significant gap in animal soundness.

Unintended consequences, arise under the strain of scientific and economic achievement. It will take time and discipline to bring traits like soundness up to speed.

I am by no means making an argument against genetic advancement. On the contrary, I am a firm believer in improvement and making wise use of all genetic selection tools. I simply see the road to change is not straight and narrow. It winds and turns with plenty of peaks and valleys, as well as, the occasional switch back. As a breeder, you need to understand the trade-offs that come with accelerated genetic selection. Can you afford to add that next unit of performance or milk? Or, should you keep pace just behind the curve and capture value as the rest of the systems catch up?

Follow this link:
Jared Wareham; The Genetic Paradox - CattleNetwork.com

Can genetics play a role in education and well-being? – Medical Xpress

July 4, 2017 Genoeconomics looks for genetic ties to life outcomes and economic behavior. Credit: Janice Kun

When Daniel Benjamin was just beginning his PhD program in economics in 2001, he attended a conference with his graduate school advisers. They took in a presentation on neuroeconomics, a nascent field dealing with how the human brain goes about making decisions.

Afterward, as they took a stroll outside, they couldn't stop talking about what they had learned, how novel and intriguing it was. What would be next, they wondered. What would come after neuroeconomics?

"The human genome project had just been completed, and we decided that even more fundamental than the brain would be genes, and that someday this was going to matter a lot for social science," said Benjamin, associate professor (research) of economics at the USC Dornsife College of Letters, Arts and Science's Center for Economic and Social Research (CESR). Indeed, his excitement that day was the foundation of a visionary academic path.

Fast forward to today. Genoeconomics is now an emerging area of social science that incorporates genetic data into the work that economists do. It's based on the idea that a person's particular combination of genes is related to economic behavior and life outcomes such as educational attainment, fertility, obesity and subjective well-being.

"There's this rich new source of data that has only become available recently," said Benjamin, also co-director of the Social Science Genetic Association Consortium, which brings about cooperation among medical researchers, geneticists and social scientists.

Collecting genetic data and creating the large data sets used by economists and other social scientists have become increasingly affordable, and new analytical methods are getting more and more powerful as these data sets continue to grow. The big challenge, he said, is figuring out how scientists can leverage this new data to address a host of important policy questions.

"We're ultimately interested in understanding how genes and environments interact to produce the kinds of outcomes people have in their lives, and then what kinds of policies can help people do better. That is really what economics is aboutand we're trying to use genetics to do even better economics."

The mission at hand

Only a handful of economists are working with genetics, but this brand of research is perfectly at home at CESR. The center, founded three years ago, was conceived as a place where visionary social science could thrive and where research could be done differently than in the past.

"Being in a place where that's the shared vision is pretty rare," said econometrician Arie Kapteyn, professor (research) of economics and CESR director. "There's no restriction on which way you want to go or what you want to do. It doesn't mean that there are no restrictions on resources, but it's the opportunity to think about your vision of what's really exciting in social science research. Then being able to actually implement it is absolutely fantastic."

The mission of CESR is discovering how people around the world live, think, interact, age and make important decisions. The center's researchers are dedicated to innovation and combining their analysis to deepen the understanding of human behavior in a variety of economic and social contexts.

"What we try to do is mold a disciplinary science in a very broad sense," Kapteyn said. "Because today's problems in society, they're really all multidisciplinary."

Case in point: Benjamin's work combining genetics and economics.

The flagship research effort for Benjamin's CESR research group deals with genes and education. In a 2016 study, the team identified variants in 74 genes that are associated with educational attainment. In other words, people who carry more of these variants, on average, complete more years of formal schooling.

Benjamin hopes to use this data in a holistic way to create a predictive tool.

"Rather than just identifying specific genes," he said, "we're also creating methods for combining the information in a person's entire genome into a single variable that can be used to partially predict how much education a person's going to get."

The young field of genoeconomics is still somewhat controversial, and Benjamin is careful to point out that individual genes don't determine behavior or outcome.

"The effect of any individual gene on behavior is extremely small," Benjamin explained, "but the effects of all the genes combined on almost any behavior we're interested in is much more substantial. It's the combined information of many genes that has predictive power, and that can be most useful for social scientists."

Learning about behavior

While the cohort of researchers actively using the available genome-wide data in this way is still somewhat limited, Benjamin says it is growing quickly.

"I think across the social sciences, researchers are seeing the potential for the data, and people are starting to use it in their work and getting excited about it, but right now it's still a small band of us trying to lay the foundations.

"We're putting together huge data sets of hundreds of thousands of peopleapproaching a million people in our ongoing work on educational attainmentbecause you need those really big sample sizes to accurately detect the genetic influences."

As CESR works to improve social welfare by informing and influencing decision-making in the public and private sectors, big data such as Benjamin's is a growing part of that process, according to Kapteyn.

"What big data reflects is the fact that nowadays there are so many other ways in which we can learn about behavior," he said. "As a result, I think we'll see many more breakthroughs and gain a much better understanding of what's going on in the world and in social science than in the past.

"I think we're really at the beginning of something pretty spectacular. What we are doing is really only scratching the surfacethere's so much more that can be done."

Explore further: Scientists find genes associated with educational attainment

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Read the rest here:
Can genetics play a role in education and well-being? - Medical Xpress

UNITAR Workshop Looks at Behavioral Insights for SDG 13 – IISD Reporting Services

27 June 2017: Member States and stakeholders discussed behavioral insights and their applications for the achievement of the Sustainable Development Goal (SDG) 13 on climate change, during a training organized by the UN Institute for Training and Research (UNITAR). The workshop aimed to build participants understanding of defaults, social norms and steps necessary for tackling climate change.

Moderator Lori Foster Thompson, North Carolina State University, opened the course, titled Behavioural Insights towards the Implementation of Sustainable Develoment Goal (SDG) 13 (Climate Action), which took place at the UN Headquarters in New York, US, on 27 June 2017. She noted that sustainable consumption and production, which is key to achieving SDG 13, is essentially about human behavior, and thus incentives to promote changes in behavior are needed. Foster Thompson highlighted the value of using behavioral insights for designing evidence-based polices. She added that even though there are pockets focused on behavioral insights that operate in different UN agencies, an overarching structure focused on behavioral insights is yet to be formalized within the system.

Elke U. Weber, Princeton University, challenged the idea of Homo Economicus who makes decisions rationally, by explaining that Homo Sapiens is not primarily a creature of rational deliberation, but rather a creature of habit who learns best from personal experience and uses emotions, associations, rules and habits to guide action. She said humans have always too many goals, often conflicting. Weber added that policy makers and communicators therefore need to find ways to activate those goals that are more forward looking and more environment friendly. She noted that inaction is the current behavioral status-quo, which was formed in a period in which people were not facing climate change issues. Weber stressed that this behavioral status-quo is the current barrier to change.

She cautioned against using fear or guilt-based messaging, explaining that even though this type of messages attract attention, they do not retain peoples attention as they tend to dissociate from unpleasant emotions. She advised that in order to keep peoples attention, messaging should be focused on effective solutions and appeal to the moral sense of people doing the right/good thing. She stressed that policy makers should not allow for behavior preferences to influence policies, but policies need to be evidence-based because people will end up adopting them.

Filippo Cavassini, Organisation for Economic Co-operation and Development (OECD), explained that the OECD conducted a world-wide mapping of the use of behavioral insights in public policy. He added that the mapping found that local governments have applied a lot in terms of behavioral insights because they are the interface with the public, and the use of behavioral insights is usually spearheaded by politicians. He gave the example of the UK, which currently has a world-wide known behavioral insights team. Cavassini explained that overall behavioral insights are applied across sectors, especially in the financial sector after the financial crisis because consumers need to be better educated about financial choices.

Cavassini noted that behavioral insights are currently mainly used in the implementation stage, while they could also be used in designing policies that are effective. He announced that the OECD will look at behavioral insights for complex policy issues, such as digital tools and how they can be used, for instance, to promote sustainable energy consumption. He concluded that, even though so far behavioral insights have been applied to individuals, there are opportunities to apply them to institutions.

Irina Feygina, Climate Central, underlined that most people do not care about climate change thus choices need to be framed through needs that are very stringent.

Mary MacLennan, London School of Economics (LSE), spoke about her experience in working with the government of Ontario, Canada. She highlighted that the use of behavioral insights builds skills across government with regards to knowledge and evidence-based policy. She said behavioral insights use in governance needs to be thought in terms of its added value for things such as cost-savings, balancing budgets or innovation. Underlining the importance of having a multidisciplinary approach to behavioral insights that brings together sociology, psychology and anthropology, MacLennan also noted challenges to work across departments and ministries. She recalled significant interest, enthusiasm and buy-in for the use of behavioral insights at the lower and highest levels of governments. She also pointed to problems and resistance with the middle management, stressing that it is much more risk-adverse.

Irina Feygina, Climate Central, underscored the importance of how choices are framed, noting that small changes to the framing of a policy or choice can improve its effectiveness. She explained that decision making is not cost-benefit but driven by needs and desires, and that attitudes and values interfere in the way we process information. She therefore called for putting peoples needs first when messaging (such as health, safety, children, capacity to strive, community safety) rather than speaking about climate change, underlining that most people do not care about climate change thus choices need to be framed through needs that are very stringent.

Feygina said people prefer narratives and stories than facts, because they have a hard time encoding facts. She added that facts are hard to feed the need to belong, which is the most stringent human need after the needs of food, shelter and safety. She stressed the need to give people very simple, attractive and simplified options, and to communicate to them that other people they admire are doing it.

In the ensuing discussion, participants underscored the need to: provide incentives and secure political courage; downgrade the scientific thinking to make it more accessible to the public at large; and look at the structural macro-systems in place, like the capitalist system built on continuous growth. They also discussed ways to design experiments with larger-systems interventions. [IISD Sources] [UNITAR Website]

Read the rest here:
UNITAR Workshop Looks at Behavioral Insights for SDG 13 - IISD Reporting Services

It Turns Out That Mike Pence Is Pretty Mainstream – National Review

I know Im referring back to an incident that feels like it happened thousands of controversies ago, but its still worth a revisit. Remember when Mike Pence was crazy and strange for reportedly not wanting to eat dinner with a woman who wasnt his wife? Well, thanks to the New York Times, we now have data about the rest of America, and itturns out that vast numbers of men and women are wary of being alone with the opposite sex.

Heres Claire Cain Miller summing up the polling results:

Many men and women are wary of a range of one-on-one situations, the poll found. Around a quarter think private work meetings with colleagues of the opposite sex are inappropriate. Nearly two-thirds say people should take extra caution around members of the opposite sex at work. A majority of women, and nearly half of men, say its unacceptable to have dinner or drinks alone with someone of the opposite sex other than their spouse.

As one might expect, theres a sliding scale of acceptability, with most people endorsing private work meetings and most rejecting private dinners or drinks. Interestingly,for all the talk that discouraging one-on-onemeetings disadvantages women, they were more likely than men to disapprove of every category of private encounter.

As Millerstates, The results show the extent to which sex is an implicit part of our interactions. Yes indeed they do, but its not just because affairs, harassment, or other inappropriate conduct might occur. The resultsalso demonstratethe extent to which fear of rumors or of even potentially false claims colors human behavior. A single accusation can destroy a reputation and derail a career. Whynot keep your office door open? Why not conduct business more in professional settings than in the intimate confines of dinner or drinks?

In my twenty-plus years of job experience in multiple private-sector and public-sector contexts the influence of private dinners on professional advancement is vastly overstated. At the same time, Ive seen multiple sexual scandals derail the most promising of careers. Given this reality, caution isnt extremist or sexist. Its wise.

Read the original:
It Turns Out That Mike Pence Is Pretty Mainstream - National Review

View from Washington: Insurers silent on climate – Business Insurance

President Donald Trump withdrew from the Paris climate agreement last month a decision I suspect the United States will quickly come to regret.

The Paris agreement reaffirmed a goal of limiting the global temperature increase below 2 degrees Celsius and committed countries to develop plans to reduce greenhouse gas emissions and regularly report on their progress. The United States, under former President Barack Obama, was one of 195 countries signing on to the agreement. But President Trumps decision to withdraw will allow countries such as China and India to further shape a global agreement that will dramatically impact the United States regardless of its lack of participation.

The backlash to the presidents decision in much of the business community and at the state and local levels was swift and unmistakable. But there was a critical voice that was missing: the U.S. insurance sector.

Perhaps it is a fear of offending customers who reject either the very idea of climate change or the fact that human behavior is a significant contributor to global warming that has kept domestic insurers, and even the trade associations that normally speak for them on political issues, mostly on the sidelines.

But that silence works against them because they are abdicating an opportunity to play a constructive role in addressing a serious threat to their own profitability, as the natural catastrophes that they are financially responsible for will only get worse without timely intervention.

Their European reinsurance counterparts are not nearly as skittish, with officials from Munich Reinsurance America Inc. and Swiss Re Ltd. denouncing the presidents decision to withdraw. They should be commended for their willingness to publicly oppose an action they know will keep the United States from being a critical player in addressing what their own research tells them is a real threat to human life and property.

Insurers are going to have to deal with the climate issue some way or the other. California Insurance Commissioner Dave Jones launched the Climate Risk Carbon Initiative in January 2016 to require insurers with $100 million in annual premiums doing business in California to disclose investments in fossil fuels and asked all insurers operating in the state to divest investments in thermal coal. He recently vowed to continue this initiative despite a threat of legal action by Republican officials in 13 states, predominantly those with major oil, gas and coal interests. As Mr. Jones stated in his response, there is overwhelming scientific evidence that climate change is real and should not be ignored.

The 2004 disaster movie The Day After Tomorrow depicted the consequences of failing to heed warnings on climate change, including devastating catastrophes in areas of the United States where they are least expected. While the movie significantly exaggerates the time frame of these events for dramatic purposes, two key elements ring true: that human behavior is contributing to a changing climate and that those in power who can act to prevent catastrophic climate change often ignore the scientific warnings until its too late.

President Trump has failed to heed these warnings. Its time for others to step up.

Original post:
View from Washington: Insurers silent on climate - Business Insurance

Traffic Engineering Rules Must Be Followed Off the Bat (Opinion) – Government Technology

(TNS) -- We were gratified, if a little perplexed, to learn that local and state transportation planners apparently awoke from a deep sleep to discover congestion on Arapahoe Avenue east of the city and a bottleneck on U.S. 36 could be improved by gasp adding lanes to accommodate the traffic volume.

It is an article of ideological dogma in the governments of Boulder and Boulder County that building new roads or lanes doesn't relieve congestion a concept known as "induced demand." In the minds of some officials, this conviction appears to have morphed into the notion that no infrastructure improvements for auto travel are ever appropriate. But a basic rule of traffic engineering still applies: Capacity must be sufficient for the smooth flow of existing demand (unless, of course, you are trying purposefully to inconvenience motorists for other political purposes).

A review of existing demand on Arapahoe between Lafayette and Boulder reveals too many cars to move efficiently on a two-lane road. With population growth and housing development certain to continue in the east county, basic traffic engineering requires the infrastructure to keep up.

This goes against the ideological position of many local officials, who continue to believe that starving motorists of space will convince them to switch to bikes or buses. Unfortunately, actual human behavior indicates this is not true. Despite all sorts of well-meaning public pressure to do just that, the percentage of commuters that drive into Boulder roughly four out of five - hasn't changed in 25 years.

As we have observed before, this is not because motorists want to confound the ideological objectives of Boulder progressives. This is because cycling is not practical for many commuters and mass transit in these parts still presents enormous first-mile, last-mile problems that extend commute times dramatically.

Having finally acknowledged the problem, some local officials remain determined to steer commuters into the behaviors those officials prefer. Hence the enthusiasm to revamp Arapahoe not to accommodate the cars already there but to create dedicated lanes for a bus rapid transit system that does not yet exist.

Boulder City Councilman Aaron Brockett had the temerity some months ago to ask how often such buses would run. Nobody knows, of course. In part, that's because it would be up to the Regional Transportation District. In part, it's because nobody knows what the market demand might be. But it would not be surprising if ideologically-driven county officials devoted large portions of the roadway to a mode few people use at the expense of the mode most people use in yet another attempt at forced behavior modification.

Officials will respond that they are fighting climate change by trying to reduce auto emissions, a laudable goal. But it is far more likely that goal will be achieved by improvements in transportation technology electrification of the automobile fleet, for example than coercion. Political progressives have every right to try to persuade their constituents to behave differently, but purposefully making them miserable to force them to come around goes against the basic concept of public service.

The ramp from Foothills Parkway onto eastbound U.S. 36 was an even more egregious example, if that's possible. When U.S. 36 was rebuilt to add an express lane in each direction, the eastbound express lane made its initial appearance tantalizingly close to the Foothills ramp, but not close enough. That left two lanes of eastbound U.S. 36 and two lanes of Foothills Parkway to merge into . . . two lanes. Naturally, it became a bottleneck, with two lanes of cars backing up on each roadway and producing more emissions, not less.

The state Department of Transportation patted itself on the back for its innovative solution last week restriping the merge area to make room for three lanes which could have been the original configuration if the express lane had started a little earlier.

"This shows how, by thinking a little differently, we can improve operations despite constrained resources and constrained funding," CDOT Executive Director Shailen Bhatt said. "This relatively low-cost project will save 200 to 700 vehicle hours per day, according to our study."

We don't want to seem ungrateful, but anyone who works in transportation for a living and was surprised that the original configuration produced a daily traffic jam might be better off choosing another line of work.

The suspicion of many commuters whose views don't seem to matter much to Boulder transportation planners is that these apparent signs of incompetence are actually intentional coercive measures intended to change commuter behavior.

But they didn't. Traveling by car remains the fastest way for most commuters to get where they're going, even accounting for increasing congestion and some poor traffic engineering along the way. Until that changes, all the lectures in the world from well-meaning officials won't change the basic calculus for people trying to get to and from work as quickly as they can.

Given that fact of human behavior, it's probably best to go back to basic traffic engineering rules and make the system operate as efficiently as possible. That reduces emissions, too.

2017 the Daily Camera (Boulder, Colo.) Distributed by Tribune Content Agency, LLC.

Read more:
Traffic Engineering Rules Must Be Followed Off the Bat (Opinion) - Government Technology